How much is the portal hypertension management market worth, and how is it expected to expand?
The portal hypertension management market size has grown strongly in recent years. It will grow from $3.07 billion in 2024 to $3.28 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to the increased prevalence of liver diseases, growth in the geriatric population, awareness and screening programs, economic burden of liver diseases, approval done for new drugs and therapies, and improvement done for diagnostic methods.
The portal hypertension management market size is expected to see strong growth in the next few years. It will grow to $4.23 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to rising investment in healthcare infrastructure, broader health insurance coverage, favorable regulatory environments and expedited approval processes, ongoing r&d activities focused on understanding the pathophysiology of portal hypertension, and remote monitoring technologies will facilitate continuous patient management. Major trends in the forecast period include growing adoption of telemedicine, continued advancements in medical technology, such as bio-engineered liver tissue, growth in personalized medicine, development of targeted therapies tailored to individual patient profiles, improved diagnostic methods, including non-invasive imaging technologies like elastography.
Get Your Free Sample of The Global Portal Hypertension Management Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16515&type=smp
What are the key drivers behind the rapid expansion of the portal hypertension management market?
An increasing prevalence of liver diseases such as hepatitis is expected to propel the growth of the portal hypertension management market going forward. Liver disease refers to a range of conditions that affect the liver’s structure or function, often leading to symptoms such as jaundice, fatigue, and abdominal pain, with causes including viral infections, alcohol abuse, or metabolic disorders. Liver diseases are occurring due to alcohol consumption, viral hepatitis infections, obesity-related fatty liver disease, and metabolic disorders. Portal hypertension management in liver disease aims to reduce pressure in the portal vein system, which helps alleviate complications such as variceal bleeding, ascites, and hepatic encephalopathy, improving patient outcomes. For instance, in September 2022, according to Cancer Australia, an Australia-based government cancer agency, around 2,905 new cases of liver cancer were diagnosed in Australia in 2022 (2,113 males and 792 females). Further, the risk of developing liver cancer by age 85 is predicted to be 1 in 103 (or 0.97%) in 2022, 1 in 70, or 1.4%, for men, and 1 in 195, or 0.51%, for women. Therefore, the increasing prevalence of liver diseases is driving the portal hypertension management market.
What is the segmentation for the portal hypertension management market?
The portal hypertension management market covered in this report is segmented –
1) By Treatment Type: Medications, Non-Surgical Procedures, Surgery
2) By Procedure Type: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Other Procedure Types
3) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Medications: Beta-Blockers, Vasodilators, Diuretics, Antibiotics, Other Medications
2) By Non-Surgical Procedures: Endoscopic Variceal Ligation (EVL), Endoscopic Sclerotherapy, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Balloon Occlusion
3) By Surgery: Liver Transplantation, Portosystemic Shunt Surgery, Surgical Decompression Of Portal Vein, Other Surgical Procedures
Order your report now for swift delivery
Who are the most influential companies in the portal hypertension management market?
Major companies operating in the portal hypertension management market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Merck & Co., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals LLC., Lupin Ltd., Daiichi Sankyo, Dr. Falk Pharma GmbH, Cumberland Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Chiasma Inc., Debiovision Inc.
What are the most influential trends expected to drive the portal hypertension management market forward?
Major companies in the portal hypertension management market are adopting advanced minimally invasive devices to enhance treatment outcomes and reduce procedural risks. Minimally invasive devices are medical instruments or tools designed to perform procedures with minimal disruption to surrounding tissues, typically through small incisions or natural body openings. For instance, in November 2023, Medtronic Plc, a US-based medical device manufacturer, received approval from the U.S. Food and Drug Administration (FDA) for Symplicity Spyral renal denervation (RDN). It is a minimally invasive device for treating hypertension. This innovative procedure employs radiofrequency energy to target nerves near the kidneys, effectively calming them to manage hypertension.
What are the major regional insights for the portal hypertension management market, and which region holds the top position?
North America was the largest region in the portal hypertension management market in 2023. The regions covered in the portal hypertension management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Portal Hypertension Management Market Report 2025 Offer?
The portal hypertension management market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Portal hypertension management refers to the treatment and prevention of complications arising from increased pressure in the portal vein system, often due to liver cirrhosis. It involves measures to reduce portal pressure, such as lifestyle changes, medications (like beta-blockers), and procedures such as variceal banding placement to prevent or manage complications such as variceal bleeding and ascites.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16515
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
